COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace

SARS-CoV-2, identified in Wuhan, China, for the first time in December 2019, is a new viral strain, which has not been previously identified in humans; it can be transmitted both by air and via direct and indirect contact; however, the most frequent way it spreads is via droplets. Like the other viruses belonging to the same family of coronaviruses, it can cause from mild flu-like symptoms, such as cold, sore throat, cough and fever, to more severe ones such as pneumonia and breathing difficulties, and it can even lead to death. Since no effective specific drug therapy has been found yet, nor any vaccine capable of limiting the spread of this pathogen, it is important for ways of preventing the spread of this infection to be established. The purpose of our research was to provide a protocol to prevent the spread of SARS-CoV-2 infection in light of the limited information related to this coronavirus. In detail, we analysed and searched targeted evidence-based guidelines issued in the various countries affected by this epidemic up till now. In addition, we analyzed the recommendations for the prevention and control of other epidemics caused by other pathogens belonging to the same family of coronaviruses or others that present the same mechanisms of transmission. General organizational measures regarding the containment and management of the epidemiological emergency of COVID-19 have been imposed by the competent authorities for an adequate and proportionate management of the evolution of the epidemiological situation. The prevention and protection organizational measures therefore aim to minimize the probability of being exposed to SARS-CoV-2. For this purpose, measures must also be taken at work to avoid new infections or even the spread of the virus where it has already been present. Furthermore, environmental measures are aimed at reducing the risk of transmission of SARS-CoV-2 to individuals through contact with infected subjects, objects, equipment, or contaminated environmental surfaces. Protective devices must be used whenever there is potentially close contact with a suspect case, especially when the potentially infected person does not wear a surgical mask that could reduce the spread of viruses in the environment. By adopting this specific prevention and protection measures recommended in the workplace, it will be possible to help overcome this COVID-19 pandemic.

[1]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[2]  D. J. Weber,et al.  Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination☆ , 2015, Journal of Hospital Infection.

[3]  James O. Lloyd-Smith,et al.  Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1 , 2020, medRxiv.

[4]  F. Kilinc A Review of Isolation Gowns in Healthcare: Fabric and Gown Properties , 2015, Journal of engineered fibers and fabrics.

[5]  L. Gostin,et al.  The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. , 2020, JAMA.

[6]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[7]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[8]  Y. Furuta,et al.  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[9]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[10]  J. Nie,et al.  Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 , 2020, Emerging microbes & infections.

[11]  Yuguo Li,et al.  Recognition of aerosol transmission of infectious agents: a commentary , 2019, BMC Infectious Diseases.

[12]  Tiziana Ramaci,et al.  Night-Time Shift Work and Related Stress Responses: A Study on Security Guards , 2020, International journal of environmental research and public health.

[13]  R. Wunderink,et al.  MERS, SARS and other coronaviruses as causes of pneumonia , 2017, Respirology.

[14]  D. Anderson,et al.  Assessment of Self-Contamination During Removal of Personal Protective Equipment for Ebola Patient Care , 2016, Infection Control & Hospital Epidemiology.

[15]  Bo Li,et al.  Insights into the cross-species evolution of 2019 novel coronavirus , 2020, Journal of Infection.

[16]  D. Batlle,et al.  Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? , 2020, Clinical science.

[17]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[18]  Joy Y. Feng,et al.  The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus , 2020, The Journal of Biological Chemistry.

[19]  P. Teunis,et al.  Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population , 2008, PloS one.

[20]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[21]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[22]  Hyeshik Chang,et al.  Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) , 2020, Experimental neurobiology.

[23]  J. Peiris,et al.  The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus , 2011, Advances in virology.

[24]  William A. Lee,et al.  Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses , 2017, Journal of medicinal chemistry.

[25]  Novel Coronavirus Pneumonia Emergency Response Epidemiol Team [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[26]  Dylan H. Morris,et al.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 , 2020, The New England journal of medicine.

[27]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[28]  Sheng-Qun Deng,et al.  Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China , 2020, Journal of clinical medicine.

[29]  B. Cowling,et al.  Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention. , 2019, Current opinion in infectious diseases.

[30]  Biao Ren,et al.  Transmission routes of 2019-nCoV and controls in dental practice , 2020, International Journal of Oral Science.

[31]  L. Hong,et al.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. , 2020, European review for medical and pharmacological sciences.

[32]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[33]  T. Singhal A Review of Coronavirus Disease-2019 (COVID-19) , 2020, The Indian Journal of Pediatrics.

[34]  A. Arvey,et al.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.

[35]  Christopher M Walker,et al.  Effect of ultraviolet germicidal irradiation on viral aerosols. , 2007, Environmental science & technology.

[36]  J. Verbeek,et al.  Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. , 2016, The Cochrane database of systematic reviews.

[37]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[38]  B. Cowling,et al.  Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention. , 2019, Current opinion in infectious diseases.

[39]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[40]  G. Kampf,et al.  Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents , 2020, Journal of Hospital Infection.

[41]  Tiina Reponen,et al.  Respiratory Performance Offered by N95 Respirators and Surgical Masks: Human Subject Evaluation with NaCl Aerosol Representing Bacterial and Viral Particle Size Range , 2008, The Annals of occupational hygiene.

[42]  D. Batlle,et al.  Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System , 2019, Biomolecules.

[43]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[44]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[45]  Tiziana Ramaci,et al.  Work-Related Stress, Physio-Pathological Mechanisms, and the Influence of Environmental Genetic Factors , 2019, International journal of environmental research and public health.

[46]  M Q Zhang,et al.  [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[47]  Guozhong He,et al.  Potential Factors Influencing Repeated SARS Outbreaks in China , 2020, International journal of environmental research and public health.

[48]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  N. White,et al.  The treatment of malaria. , 1996, The New England journal of medicine.

[50]  J. Penninger,et al.  Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[51]  B. Crook,et al.  Effectiveness of surgical masks against influenza bioaerosols. , 2013, The Journal of hospital infection.

[52]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[53]  J. Garcia,et al.  Chloroquine is a potent pulmonary vasodilator that attenuates hypoxia‐induced pulmonary hypertension , 2017, British journal of pharmacology.

[54]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[55]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[56]  W. Zuo,et al.  Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov , 2020, bioRxiv.

[57]  Federico M Giorgi,et al.  Genomic variance of the 2019‐nCoV coronavirus , 2020, Journal of medical virology.

[58]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).